URL Brings Gout Drug To Takeda | Chemical & Engineering News
Volume 90 Issue 16 | p. 23 | Concentrates
Issue Date: April 16, 2012

URL Brings Gout Drug To Takeda

Department: Business
Keywords: gout

Takeda Pharmaceuticals has agreed to acquire Philadelphia-based URL Pharmaceuticals for $800 million up front plus unspecified performance-based milestone payments. URL, which had $600 million in sales last year, specializes in gout treatment. Its lead product, Colcrys, had 2011 sales of $430 million. Takeda’s lead gout treatment is Uloric, used to lower blood uric acid levels in adults with gout.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment